US biotechnology company Genzyme has bought the privately-owned Swiss company Sygena Ltd for 19 million Swiss francs ($14.7 million). Located at Liestal, near Basel, Sygena is the first Swiss firm to be acquired by an American biotechnology company, according to Genzyme, which says this will provide it with manufacturing facilities in continental Europe.
Joining Genzyme's pharmaceuticals and fine chemicals division, Sygena will provide the US firm with substantial technology and increased capacity to produce drugs and pharmaceutical ingredients, including synthetic peptides and phospholipids which play an important role in the development of gene therapy and a number of new drug delivery formulations. Genzyme says it will also significantly expand its number and scope of manufacturing partnerships with drug and biotechnology companies. Sygena has 45 employees and produced revenues of 7.2 million francs in 1993.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze